Technical Data
ACVR2B, NT (Activin Receptor Type 2B, Activin Receptor Type IIB, ACTR-IIB) (FITC)
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. ACVR2B (activin A type IIB receptor) displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor.

Suitable for use in Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000
Immunohistochemistry: 1:50-1:100
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Do not freeze FITC conjugates. Light sensitive. Aliquots are stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
200ul4C Do Not FreezeBlue IceHumanRabbit
As reported
Synthetic peptide corresponding to the N-terminal region of human ACVR2B (KLH).
Purified by immunoaffinity chromatography.
Supplied as a liquid in PBS, pH 7.2. Contains ~0.09% sodium azide. Conjugated to FITC.
Recognizes human ACVR2B. Species crossreactivity: mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1.Harrison, C.A., et al., J. Biol. Chem. 279(27):28036-28044 (2004). 2.Martins da Silva, S.J., et al., Dev. Biol. 266(2):334-345 (2004). 3.Casagrandi, D., et al., Mol. Hum. Reprod. 9(4):199-203 (2003). 4.Shin, B.K., et al., J. Biol. Chem. 278(9):7607-7616 (2003). 5.Schneider-Kolsky, M.E., et al., Placenta 23(4):294-302 (2002).